Marseille
France
53
2026-03-05
The entities that hold a legal rights for patent applications filed by inventor Olive Daniel:
Daniel Olive from Marseille, FR has applied for patents for these inventions. The list has both pending applications and granted patents:
NOVEL ANTI-NECTIN-4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#2 | 2026-01-22ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD
#3 | 2025-06-19Novel formats of anti-CD28/sPD-1 fusion constructs
#4 | 2025-04-24BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS
#5 | 2025-04-24ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD
#6 | 2025-01-16ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF
#7 | 2024-06-06ANTI-NECTIN-4 ANTIBODY AMANITIN CONJUGATES
#8 | 2024-05-30ANTI-NECTIN-4-ANTIBODY EXATECAN CONJUGATES
#9 | 2024-04-11ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
#10 | 2024-02-01Anti-nectin-4-antibodies and uses thereof
#11 | 2023-10-12Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
#12 | 2023-09-14ANTI-CD277 ANTIBODIES AND USES THEREOF
#13 | 2023-08-31ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS
#14 | 2023-06-15ANTIBODIES HAVING SPECIFICITY FOR BTLA AND USES THEREOF
#15 | 2023-06-15ANTIBODIES HAVING SPECIFICITY FOR NECTIN-4 AND USES THEREOF
#16 | 2023-06-15NEW METHOD TO TREAT CUTANEOUS T-CELL LYMPHOMAS AND TFH DERIVED LYMPHOMAS
#17 | 2022-08-11NOVEL ANTI-CD25 ANTIBODIES
#18 | 2022-05-26Antibodies having specificity for BTN2 and uses thereof
#19 | 2022-04-14Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
#20 | 2022-03-10BTN3A binding proteins and uses thereof
#21 | 2020-12-03Anti-CD277 antibodies
#22 | 2020-11-05Antibodies Directed Against ICOS and Uses Thereof
#23 | 2020-09-10Antibodies having specificity for BTN2 and uses thereof
#24 | 2019-11-21Antibodies directed against ICOS and uses thereof
#25 | 2019-10-17Antibodies directed against ICOS and uses thereof
#26 | 2019-07-04Anti-CD277 antibodies
#27 | 2018-08-30Antibodies directed against ICOS and uses thereof
#28 | 2018-08-30Antibodies having specificity to nectin-4 and uses thereof
#29 | 2018-08-23NEW BIOMARKER FOR OUTCOME IN AML PATIENTS
#30 | 2018-06-07BTLA Antibodies and Uses Thereof
#31 | 2018-03-15NON-INVASIVE IMAGING OF TUMOR PD-L1 EXPRESSION
#32 | 2018-03-08ANTI-PD-L1 IMMUNOTOXIN FOR USE IN THERAPY
#33 | 2018-02-01ICOS BINDING PROTEINS
#34 | 2017-09-28Antibodies directed against ICOS for treating graft-versus-host disease
#35 | 2017-08-17Antibodies directed against ICOS and uses thereof
#36 | 2017-04-13NEW BIOMARKER FOR OUTCOME IN AML PATIENTS
#37 | 2016-11-17NOVEL ANTIGEN PEPTIDE AND USES THEREOF
#38 | 2016-09-15Antibodies directed against ICOS and uses thereof
#39 | 2016-06-02COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY
#40 | 2016-05-05ANTAGONIST OF THE BTLA/HVEM INTERACTION FOR USE IN THERAPY
#41 | 2016-03-31Antagonist of the BTLA/HVEM interaction for use in therapy
#42 | 2015-12-10ANTI-CD277 ANTIBODIES AND USES THEREOF
#43 | 2015-08-27Antibodies directed against ICOS for treating graft-versus-host disease
#44 | 2015-05-28BTLA antibodies and uses thereof
#45 | 2014-11-13PD-1 antibodies and PD-L1 antibodies and uses thereof
#46 | 2014-10-30ANTI-CD277 ANTIBODIES AND USES THEREOF
#47 | 2014-06-26Antigen peptide and uses thereof
#48 | 2014-03-27Antibodies directed against ICOS and uses thereof
#49 | 2012-03-15BTLA Antibodies and Uses Thereof
#50 | 2012-02-16PD-1 antibodies and PD-L1 antibodies and uses thereof
#51 | 2011-07-21Method for treating and diagnosing hematologic malignancies
#52 | 2010-08-05Ligands of HVEM for treating hematologic malignancies
#53 | 2008-02-14Anti-CD28 antibody
703203 ⎘